Haemonetics reported first quarter revenue of $339 million, increasing 6% reported and organic, and raised its full-year fiscal 2027 guidance. Adjusted earnings per diluted share increased 4% to $1.14. Plasma revenue grew 8% organic, driven by double-digit growth in disposables globally and the rollout of Persona PLUS. MedSurg revenue increased 6% year-over-year reported and organic to $148 million, with Blood Management Technologies growing 8% organically and Vascular Closure up low-double-digits. The company now expects fiscal 2027 reported revenue growth of 5% to 8% and organic growth of 4% to 7%, while reaffirming free cash flow conversion of approximately 80% of adjusted net income.
Haemonetics CorporationRaised fiscal 2027 guidance and reported strong Q1 revenue growth.
